Circulation Journal
Online ISSN : 1347-4820
Print ISSN : 1346-9843
ISSN-L : 1346-9843
Safety and Efficacy of Human Muse Cell-Based Product for Acute Myocardial Infarction in a First-in-Human Trial
Toshiyuki NodaKazuhiko NishigakiShinya Minatoguchi
著者情報
ジャーナル フリー HTML 早期公開
電子付録

論文ID: CJ-20-0307

詳細
抄録

Background:Because ST-elevation myocardial infarction (STEMI) extensively damages the heart, regenerative therapy with pluripotent stem cells such as multilineage-differentiating stress enduring (Muse) cells is required.

Methods and Results:In a first-in-human study, 3 STEMI patients with a left ventricular ejection fraction (LVEF) ≤45% after successful percutaneous coronary intervention received intravenously 1.5×107cells of a human Muse cell-based product, CL2020. The safety and efficacy on LVEF and wall motion score index (WMSI) were evaluated for 12 weeks. No adverse drug reaction was noted. LVEF and WMSI were markedly improved.

Conclusions:The first-in-human intravenous administration of CL2020 was safe and markedly improved LV function in STEMI patients.

著者関連情報
© 2020 THE JAPANESE CIRCULATION SOCIETY
feedback
Top